Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Celcuity LLC (CELC)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Celcuity's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
17.67 +0.01    +0.06%
15:59:59 - Closed. Currency in USD ( Disclaimer )
After Hours
17.67
-0.00
-0.00%
16:02:25 - Real-time Data
  • Volume: 284,562
  • Bid/Ask: 11.01 / 19.39
  • Day's Range: 17.31 - 17.97
Type:  Equity
Market:  United States
Celcuity 17.67 +0.01 +0.06%

Celcuity LLC Company Profile

 
Get an in-depth profile of Celcuity LLC, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

45

Equity Type

ORD

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company’s CELsignia diagnostic platform uses a patient’s living tumor cells to identify the specific abnormal cellular process driving a patient’s cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Contact Information

Address 16305–36th Avenue North Suite 100
Minneapolis, 55446
United States
Phone 763 392 0767
Fax -

Top Executives

Name Age Since Title
Mothaffar F. Rimawi - 2019 Member of Scientific Advisory Board
Lee S. Schwartzberg - 2019 Member of Scientific Advisory Board
Richard E. Buller 71 2019 Independent Director
Manfred Auer - - Member of Scientific Advisory Board
Mark D. Pegram - - Member of Scientific Advisory Board
Stanley M. Marks 74 - Member of Scientific Advisory Board
Adam M. Brufsky - - Member of Scientific Advisory Board
Lance G. Laing 59 2012 Co-Founder, Chief Science Officer, VP, Secretary & Director
Brian F. Sullivan 59 2012 Co-Founder, Chairman & CEO
Edward Greeno - - Member of Scientific Advisory Board
Richard J. Nigon 74 2017 Independent Director
Carol Lange - - Member of Scientific Advisory Board
Ronald C. McGlennen - - Member of Scientific Advisory Board
Benita Katzenellenbogen - - Member of Scientific Advisory Board
Sara Hurvitz - - Member of Scientific Advisory Board
David F. Dalvey 64 2014 Independent Director
John Katzenellengogen - - Member of Scientific Advisory Board
Leo T. Furcht 75 2019 Independent Director
Ben Ho Park - 2020 Member of Scientific Advisory Board
Bora Lim - 2020 Member of Scientific Advisory Board
Hung Khong - 2021 Member of Scientific Advisory Board
Alberto Montero - 2021 Member of Scientific Advisory Board
Polly A. Murphy 58 2022 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

CELC Comments

Write your thoughts about Celcuity LLC
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email